Single User License
INR 136060
Site License
INR 272120
Corporate User License
INR 408180

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Pipeline Review, H1 2015

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Pipeline Review, H1 2015', provides an overview of the Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 7

List of Figures 8

Introduction 9

Global Markets Direct Report Coverage 9

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Overview 10

Therapeutics Development 11

Pipeline Products for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Overview 11

Pipeline Products for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Comparative Analysis 12

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Therapeutics under Development by Companies 13

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Therapeutics under Investigation by Universities/Institutes 16

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Pipeline Products Glance 17

Late Stage Products 17

Clinical Stage Products 18

Early Stage Products 19

Unknown Stage Products 20

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Products under Development by Companies 21

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Products under Investigation by Universities/Institutes 24

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Companies Involved in Therapeutics Development 25

Aeolus Pharmaceuticals, Inc. 25

Bolder Biotechnology, Inc. 26

Cantex Pharmaceuticals, Inc. 27

Cellerant Therapeutics, Inc. 28

Cleveland BioLabs, Inc. 29

Gamida Cell Ltd. 30

Humanetics Corporation 31

Meabco A/S 32

NeoStem, Inc. 33

Neumedicines Inc. 34

Onconova Therapeutics, Inc. 35

Piramal Enterprises Limited 36

Pluristem Therapeutics Inc. 37

Priaxon AG 38

ProCertus BioPharm Inc. 39

RDD Pharma Ltd. 40

RxBio, Inc. 41

Soligenix, Inc. 42

Terapio Corporation 43

Tonix Pharmaceuticals Holding Corp. 44

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Therapeutics Assessment 45

Assessment by Monotherapy Products 45

Assessment by Target 46

Assessment by Mechanism of Action 48

Assessment by Route of Administration 50

Assessment by Molecule Type 52

Drug Profiles 54

517-PXN-Drug Profile 54

Product Description 54

Mechanism of Action 54

R&D Progress 54

AEOL-10171-Drug Profile 55

Product Description 55

Mechanism of Action 55

R&D Progress 55

BBT-007-Drug Profile 56

Product Description 56

Mechanism of Action 56

R&D Progress 56

BBT-015-Drug Profile 57

Product Description 57

Mechanism of Action 57

R&D Progress 57

BBT-018-Drug Profile 58

Product Description 58

Mechanism of Action 58

R&D Progress 58

BBT-045-Drug Profile 59

Product Description 59

Mechanism of Action 59

R&D Progress 59

BCN-057-Drug Profile 60

Product Description 60

Mechanism of Action 60

R&D Progress 60

BIO-300-Drug Profile 61

Product Description 61

Mechanism of Action 61

R&D Progress 61

BP-C2-Drug Profile 64

Product Description 64

Mechanism of Action 64

R&D Progress 64

CLT-009-Drug Profile 65

Product Description 65

Mechanism of Action 65

R&D Progress 65

EDL-2000-Drug Profile 66

Product Description 66

Mechanism of Action 66

R&D Progress 66

entolimod-Drug Profile 67

Product Description 67

Mechanism of Action 67

R&D Progress 67

EWA-001-Drug Profile 69

Product Description 69

Mechanism of Action 69

R&D Progress 69

GC-003-Drug Profile 70

Product Description 70

Mechanism of Action 70

R&D Progress 70

GC-4403-Drug Profile 71

Product Description 71

Mechanism of Action 71

R&D Progress 71

GC-4419-Drug Profile 72

Product Description 72

Mechanism of Action 72

R&D Progress 72

JP4-039-Drug Profile 73

Product Description 73

Mechanism of Action 73

R&D Progress 73

NMIL-121-Drug Profile 75

Product Description 75

Mechanism of Action 75

R&D Progress 75

P-276-Drug Profile 77

Product Description 77

Mechanism of Action 77

R&D Progress 77

Peptide to Agonize GHSR-1a for Sepsis, Acute Radiation Syndrome and Acute Ischemic Stroke-Drug Profile 79

Product Description 79

Mechanism of Action 79

R&D Progress 79

PGX-100-Drug Profile 80

Product Description 80

Mechanism of Action 80

R&D Progress 80

PLX-RAD-Drug Profile 82

Product Description 82

Mechanism of Action 82

R&D Progress 82

PrC-210-Drug Profile 85

Product Description 85

Mechanism of Action 85

R&D Progress 85

recilisib sodium-Drug Profile 86

Product Description 86

Mechanism of Action 86

R&D Progress 86

Recombinant Protein for Sepsis, Inflammatory bowel disease, Acute radiation syndrome and Ischemic organ injury-Drug Profile 88

Product Description 88

Mechanism of Action 88

R&D Progress 88

romyelocel-L-Drug Profile 89

Product Description 89

Mechanism of Action 89

R&D Progress 89

RP-239X-Drug Profile 90

Product Description 90

Mechanism of Action 90

R&D Progress 90

rusalatide acetate-Drug Profile 91

Product Description 91

Mechanism of Action 91

R&D Progress 91

Rx-100-Drug Profile 94

Product Description 94

Mechanism of Action 94

R&D Progress 94

RX-101-Drug Profile 96

Product Description 96

Mechanism of Action 96

R&D Progress 96

SGX-201-Drug Profile 97

Product Description 97

Mechanism of Action 97

R&D Progress 97

Small Molecule for Radiation Proctitis-Drug Profile 98

Product Description 98

Mechanism of Action 98

R&D Progress 98

Small Molecules for Radiation and Chemical Toxicity-Drug Profile 99

Product Description 99

Mechanism of Action 99

R&D Progress 99

Small Molecules for Radiation Toxicity-Drug Profile 100

Product Description 100

Mechanism of Action 100

R&D Progress 100

Small Molecules to Inhibit NO Synthase for Toxicology, Metabolic and Dermatology-Drug Profile 101

Product Description 101

Mechanism of Action 101

R&D Progress 101

ST-7-Drug Profile 102

Product Description 102

Mechanism of Action 102

R&D Progress 102

Stem Cell Therapy for Radiation Exposure-Drug Profile 103

Product Description 103

Mechanism of Action 103

R&D Progress 103

SY-303A-Drug Profile 104

Product Description 104

Mechanism of Action 104

R&D Progress 104

SY-513-Drug Profile 105

Product Description 105

Mechanism of Action 105

R&D Progress 105

TPO-7630-Drug Profile 106

Product Description 106

Mechanism of Action 106

R&D Progress 106

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Recent Pipeline Updates 108

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Dormant Projects 120

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Product Development Milestones 123

Featured News & Press Releases 123

Jan 12, 2015: Cleveland BioLabs Receives Department of Defense Support to Further Development of Entolimod as a Medical Radiation Countermeasure 123

Sep 11, 2014: Cellerant Awarded $47.5 Million Under Existing U.S. Government Contract to Support Development of CLT-008 123

Sep 03, 2014: Cleveland BioLabs Announces Green Light to Submit Pre-Emergency Use Authorization Application for Entolimod 124

Apr 18, 2014: Neumedicines Publishes Clinical Data Demonstrating Safety and Hematopoietic and Immune Effects of HemaMax (rHuIL-12), a Radiation Medical Countermeasure 125

Apr 15, 2014: Neumedicines Announces Publication of Phase II-Equivalent Data Demonstrating the Survival Effect of HemaMax (rHuIL-12), a Radiation Medical Countermeasure 126

Feb 25, 2014: Humanetics Enters Into Cooperative Research and Development Agreement With the U.S. Army Medical Research Institute of Chemical Defense 127

Feb 03, 2014: U.S. National Institutes of Health to Commence New Study of Pluristem's PLX Cells for Acute Radiation Syndrome Treatment 127

Jan 23, 2014: Cleveland BioLabs Provides Update on Barda Development Proposal 128

Jan 09, 2014: Neumedicines to Feature HemaMax Study Results in Presentation at Biotech Showcase Conference 128

Dec 13, 2013: Neumedicines Presents HemaMax Clinical Data at the ASH Conference 129

Appendix 131

Methodology 131

Coverage 131

Secondary Research 131

Primary Research 131

Expert Panel Validation 131

Contact Us 131

Disclaimer 132

List of Tables

Number of Products under Development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome), H1 2015 11

Number of Products under Development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Comparative Analysis, H1 2015 12

Number of Products under Development by Companies, H1 2015 14

Number of Products under Development by Companies, H1 2015 (Contd..1) 15

Number of Products under Investigation by Universities/Institutes, H1 2015 16

Comparative Analysis by Late Stage Development, H1 2015 17

Comparative Analysis by Clinical Stage Development, H1 2015 18

Comparative Analysis by Early Stage Development, H1 2015 19

Comparative Analysis by Unknown Stage Development, H1 2015 20

Products under Development by Companies, H1 2015 21

Products under Development by Companies, H1 2015 (Contd..1) 22

Products under Development by Companies, H1 2015 (Contd..2) 23

Products under Investigation by Universities/Institutes, H1 2015 24

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Pipeline by Aeolus Pharmaceuticals, Inc., H1 2015 25

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Pipeline by Bolder Biotechnology, Inc., H1 2015 26

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Pipeline by Cantex Pharmaceuticals, Inc., H1 2015 27

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Pipeline by Cellerant Therapeutics, Inc., H1 2015 28

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Pipeline by Cleveland BioLabs, Inc., H1 2015 29

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Pipeline by Gamida Cell Ltd., H1 2015 30

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Pipeline by Humanetics Corporation, H1 2015 31

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Pipeline by Meabco A/S, H1 2015 32

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Pipeline by NeoStem, Inc., H1 2015 33

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Pipeline by Neumedicines Inc., H1 2015 34

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Pipeline by Onconova Therapeutics, Inc., H1 2015 35

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Pipeline by Piramal Enterprises Limited, H1 2015 36

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Pipeline by Pluristem Therapeutics Inc., H1 2015 37

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Pipeline by Priaxon AG, H1 2015 38

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Pipeline by ProCertus BioPharm Inc., H1 2015 39

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Pipeline by RDD Pharma Ltd., H1 2015 40

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Pipeline by RxBio, Inc., H1 2015 41

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Pipeline by Soligenix, Inc., H1 2015 42

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Pipeline by Terapio Corporation, H1 2015 43

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Pipeline by Tonix Pharmaceuticals Holding Corp., H1 2015 44

Assessment by Monotherapy Products, H1 2015 45

Number of Products by Stage and Target, H1 2015 47

Number of Products by Stage and Mechanism of Action, H1 2015 49

Number of Products by Stage and Route of Administration, H1 2015 51

Number of Products by Stage and Molecule Type, H1 2015 53

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Therapeutics-Recent Pipeline Updates, H1 2015 108

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Dormant Projects, H1 2015 120

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Dormant Projects (Contd..1), H1 2015 121

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Dormant Projects (Contd..2), H1 2015 122

List of Figures

Number of Products under Development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome), H1 2015 11

Number of Products under Development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Comparative Analysis, H1 2015 12

Number of Products under Development by Companies, H1 2015 13

Number of Products under Investigation by Universities/Institutes, H1 2015 16

Comparative Analysis by Clinical Stage Development, H1 2015 18

Comparative Analysis by Early Stage Products, H1 2015 19

Assessment by Monotherapy Products, H1 2015 45

Number of Products by Top 10 Targets, H1 2015 46

Number of Products by Stage and Top 10 Targets, H1 2015 46

Number of Products by Top 10 Mechanism of Actions, H1 2015 48

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 48

Number of Products by Top 10 Routes of Administration, H1 2015 50

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 51

Number of Products by Top 10 Molecule Types, H1 2015 52

Number of Products by Stage and Top 10 Molecule Types, H1 2015 52

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Aeolus Pharmaceuticals, Inc.

Bolder Biotechnology, Inc.

Cantex Pharmaceuticals, Inc.

Cellerant Therapeutics, Inc.

Cleveland BioLabs, Inc.

Gamida Cell Ltd.

Humanetics Corporation

Meabco A/S

NeoStem, Inc.

Neumedicines Inc.

Onconova Therapeutics, Inc.

Piramal Enterprises Limited

Pluristem Therapeutics Inc.

Priaxon AG

ProCertus BioPharm Inc.

RDD Pharma Ltd.

RxBio, Inc.

Soligenix, Inc.

Terapio Corporation

Tonix Pharmaceuticals Holding Corp.

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Therapeutic Products under Development, Key Players in Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Therapeutics, Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Pipeline Overview, Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Pipeline, Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com